OBI Pharma CEO Wang Hui-chun Retires End of April, Stock Hits Limit Down Today
OBI Pharma announced the sudden retirement of CEO Wang Hui-chun on April 30. The unexpected news shocked the biotech sector, sending the stock limit down. The company assures R&D and operations remain unaffected.
📋 Article Processing Timeline
- 📰 Published: April 23, 2026 at 17:20
- 🔍 Collected: April 23, 2026 at 17:32 (11 min after Published)
- 🤖 AI Analyzed: April 23, 2026 at 18:58 (1h 26m after Collected)
(Central News Agency reporter He Hsiu-ling, Taipei, 23rd) OBI Pharma announced on the 22nd that its CEO (General Manager) Wang Hui-chun had applied for retirement, effective April 30. A board meeting is scheduled on the same day to discuss succession candidates and related arrangements. Since Wang just recently gave a media interview, this announcement sparked heated discussions in the biotech circle, and OBI Pharma's stock price hit limit down today, closing at NT$32.9.
OBI Pharma issued a press release today stating that various operations and R&D processes are continually advancing, and existing cooperation and business negotiations are proceeding according to plan, unaffected by this personnel change.
OBI Pharma stated that since taking over as CEO in 2023, Wang Hui-chun has led the company's transformation, focusing on the Antibody-Drug Conjugate (ADC) field, and promoting adjustments in R&D direction and resource allocation. OBI Pharma has built a patented next-generation conjugation technology platform, integrating proprietary conjugation and linker technologies to support process scale-up and promote the development of next-generation ADCs, further advancing R&D layouts such as bispecific antibodies and dual-payload designs to tackle challenges like tumor heterogeneity and drug resistance.
OBI Pharma pointed out that it will advance ADC-related R&D and international cooperation according to its established strategy, and the board of directors will carefully plan subsequent operations and personnel arrangements to support the company's sustainable development. (Editor: Chai Si-chia) 1150423
OBI Pharma issued a press release today stating that various operations and R&D processes are continually advancing, and existing cooperation and business negotiations are proceeding according to plan, unaffected by this personnel change.
OBI Pharma stated that since taking over as CEO in 2023, Wang Hui-chun has led the company's transformation, focusing on the Antibody-Drug Conjugate (ADC) field, and promoting adjustments in R&D direction and resource allocation. OBI Pharma has built a patented next-generation conjugation technology platform, integrating proprietary conjugation and linker technologies to support process scale-up and promote the development of next-generation ADCs, further advancing R&D layouts such as bispecific antibodies and dual-payload designs to tackle challenges like tumor heterogeneity and drug resistance.
OBI Pharma pointed out that it will advance ADC-related R&D and international cooperation according to its established strategy, and the board of directors will carefully plan subsequent operations and personnel arrangements to support the company's sustainable development. (Editor: Chai Si-chia) 1150423